Imidomics operates a data‑driven Clinical Discovery Engine that integrates longitudinal clinical, epidemiological and multi‑omics data from over 17,000 immune‑mediated inflammatory disease (IMID) patients and controls. Using this proprietary platform, the company identifies first‑in‑class drug targets and predictive biomarkers to enable pharmaceutical partners to develop and stratify new therapies for eight IMID indications.
Funding
$16.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with immune‑mediated inflammatory diseases (IMIDs) often receive therapies that are ineffective, cause resistance, or lack biomarkers to identify who will benefit, leading to prolonged disease, reduced quality of life, and high healthcare costs.
Solution
Imidomics leverages a proprietary Clinical Discovery Engine that integrates longitudinal clinical data, extensive epidemiological variables, and multi‑omics profiles from over 17,000 IMID patients and controls. By combining this patient‑centric data set with deep immunology expertise and bioinformatics, the company discovers first‑in‑class drug targets and predictive disease markers. The platform supports target prioritization, biomarker identification, and patient stratification to guide the development of new medicines and companion diagnostics. Partnerships with pharmaceutical companies enable faster, lower‑risk translation of these discoveries into clinical candidates across eight IMID indications.
Target Audience
Pharmaceutical and biotech companies seeking novel, data‑validated targets and patient‑stratification biomarkers for immune‑mediated inflammatory diseases.
Features
- Clinical network across Spain and Paraguay providing access to cross‑sectional and longitudinal patient samples and data
- ISO‑certified IMID‑Biobank storing >1 million vials of blood, urine, and tissue specimens from >17,000 subjects
- Multi‑omics generation (genomics, transcriptomics, proteomics, etc.) integrated with >10,000 clinical and >150 epidemiological variables
- Proprietary data‑driven Clinical Discovery Engine that combines data collection, generation, and analytics for target discovery and biomarker identification
- In‑house bioinformatics and machine‑learning pipelines to prioritize first‑in‑class targets and define responsive patient sub‑populations
- Collaboration model with industry partners to advance identified targets into drug discovery and development programs